Suchergebnisse - "Hickish, Tamas"

PubPharm (104)

1

The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer

enthalten in: Nature | 2024

von Abraham, J. | Pinilla, K. | Dayimu, A. | +42

2

A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer

enthalten in: British journal of cancer | 2024

von Holt, S. | Verrill, M. | Pettit, L. | +12

3

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Coakley, M. | Villacampa, G. | Sritharan, P. | +21

4

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer : Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Ring, A. | Kilburn, L. | Pearson, A. | +21

5

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2) : an open-label, multicenter, phase II trial

enthalten in: Breast cancer research and treatment | 2022

von Hickish, T. | Mehta, A. | Liu, M. | +11

6

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

enthalten in: Breast cancer research and treatment | 2022

von Hickish, T. | Mehta, A. | Liu, M. | +11

7

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

enthalten in: Breast cancer research and treatment | 2022

von Hickish, T. | Mehta, A. | Liu, M. | +11

8

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

enthalten in: Breast cancer research and treatment | 2022

von Hickish, T. | Mehta, A. | Liu, M. | +11

9

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC) : long-term results of a multicentre, randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2020

von Bridgewater, J. | Pugh, S. | Maishman, T. | +66

CommentIn: Lancet Oncol. 2020 Mar;21(3):324-326. - PMID 32014120

10

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer : 3-year follow-up of the SCOT non-inferiority RCT

enthalten in: Health technology assessment (Winchester, England) | 2019

von Iveson, T. | Boyd, K. | Kerr, R. | +34

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]